Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Receptor tyrosine kinase antibodies bind growth factor receptors such as epidermal growth factor receptor (EGFR). Cetuximab, panitumumab and necitumumab block ligand binding to EGFR, and amivantamab binds both EGFR and the MET receptor. Trastuzumab, pertuzumab and margetuximab bind distinct epitopes of the HER2 receptor, and patritumab targets HER3 on tumor cells. Teprotumumab binds insulin-like growth factor 1 receptor (IGF-1R), and onartuzumab is a one-armed antibody against MET. Further antibodies target fibroblast growth factor receptors, AXL, EphA2, KIT and protein tyrosine kinase 7 (PTK7).
Elegrobart is an IgG1-κ monoclonal antibody that targets the human insulin-like growth factor 1 receptor (IGF1R). This reagent is valuable for investigating diseases linked to dysregulated IGF1R signaling pathways, with a particular focus on thyroid eye disease. Researchers can utilize Elegrobart to explore the role of IGF1R in cellular growth and differentiation, advancing understanding of related pathological conditions.
Out of stock
All 3 sizes
Synonyms: PF-06647020; ABBV-647; h6M24-vc0101
Cofetuzumab pelidotin is a targeted antibody-drug conjugate (ADC) that inhibits PTK7, consisting of a humanized anti-PTK7 monoclonal antibody and an auristatin microtubule inhibitor payload linked by a cleavable valine-citrulline linker. With a drug-to-antibody ratio (DAR) of 4, it demonstrates binding to cell-surface PTK7 with an EC50 of 1153 pM as evidenced by flow cytometry. Cofetuzumab pelidotin exhibits potential effectiveness in the research of solid tumors, enabling exploration of novel therapeutic strategies.
Synonyms: GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2 (HER2), a member of the epidermal growth factor receptor family implicated in the progression of various cancers. Timigutuzumab is suitable for preclinical research on HER2-driven oncogenesis, targeted therapy development, and antibody-mediated cytotoxicity.
Anti-c-RET is a monoclonal antibody targeting the receptor tyrosine kinase RET (c-RET), which is expressed in neural crest-derived tumors such as neuroblastoma and in dopaminergic neurons of the substantia nigra. This antibody is useful for studying RET signaling in the context of oncogenesis and neurodegenerative disorders, including Parkinson’s disease.
Anti-FGF19 (clone 1A6) is a humanized monoclonal antibody that selectively binds fibroblast growth factor 19 (FGF19), a key mitogen implicated in hepatocellular carcinoma (HCC). This antibody demonstrates antitumor activity by disrupting FGF19-mediated signaling, and is suitable for research in liver cancer models and FGFR4 pathway modulation.
Margetuximab is a chimeric anti-HER2 IgG1 monoclonal antibody engineered with an optimized Fc domain to enhance antibody-dependent cellular cytotoxicity (ADCC). With an EC₅₀ of 39.33 ng/mL, Margetuximab is used in the study of HER2-positive metastatic breast cancer and immune effector cell engagement.
Amivantamab (FUT8-KO) is a recombinant anti-EGFR-MET monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). The absence of fucose on this antibody significantly enhances its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. Functionally, Amivantamab (FUT8-KO) effectively inhibits ligand binding to EGFR and MET receptors, facilitates the endocytosis and subsequent degradation of receptor-antibody complexes, and promotes Fc-dependent cytokinesis in macrophages as well as ADCC in natural killer cells. This antibody is pivotal for research focused on the molecular mechanisms of cancer cell signaling and immune response modulation.
Teprotumumab is a human monoclonal antibody that acts as an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R). This antibody specifically targets and binds to the extracellular α-subunit domain of IGF-1R, which is crucial for its ligand-binding activity. By doing so, Teprotumumab effectively blocks the receptor's interaction with its ligands, thereby inhibiting downstream signaling pathways. The antibody has been shown to impede both thyroid-stimulating hormone (TSH) and IGF-1 mediated actions in fibrocytes, leading to a reduction in TSH-dependent interleukin-6 (IL-6) and interleukin-8 (IL-8) expression, as well as Akt phosphorylation. Teprotumumab is primarily utilized in research focused on thyroid-associated ophthalmopathy, providing a valuable tool for studying the pathophysiology and potential therapeutic interventions for this condition.
The Anti-ERBB1/EGFR/HER1 Antibody is a recombinant human monoclonal antibody produced in CHO cells, specifically targeting ERBB1/EGFR/HER1. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for studies involving the modulation and function of the ERBB1/EGFR/HER1 receptor in various cellular processes, including cell growth and differentiation.
U3-1784 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting FGFR4/CD334. This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human lambda (huλ) light chain, with an estimated molecular weight of 150 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended.
Bemarituzumab is a humanized IgG1 monoclonal antibody designed to selectively target and inhibit FGFR2b (fibroblast growth factor receptor 2b). By blocking the binding and activation of fibroblast growth factors to FGFR2b, Bemarituzumab effectively impedes cellular processes that contribute to tumor growth and proliferation. This antibody has demonstrated significant antitumor activity in clinical studies, particularly in the context of gastric and breast cancers, making it a valuable tool for research in oncology and targeted therapy development.
Synonyms: BGB149
Tilvestamab (BGB149) is a humanized monoclonal antibody specifically targeting the AXL receptor tyrosine kinase. By effectively blocking AXL-mediated signaling pathways, Tilvestamab significantly reduces Gas6-induced AXL activation in 786-0-Luc renal cell carcinoma (RCC) cells and subsequently inhibits AKT phosphorylation. This antibody is particularly valuable in cancer research focusing on conditions characterized by overexpression of AXL, such as renal cell carcinomas.
Synonyms: GB-221
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody specifically designed to target EGFR2. It is produced using the CHO DG44 expression system derived from Chinese Hamster Ovary cells, ensuring high fidelity and stability in the expressed antibody. This product is pivotal for research focusing on the role of EGFR2 in various biological processes and diseases.
Eglatoprutug is a humanized IgG1-kappa monoclonal antibody that targets the c-Kit receptor. This antibody has been engineered for high specificity and affinity in binding to the c-Kit, which is commonly expressed in various cell types and is involved in numerous cellular processes, including signal transduction and cell proliferation. Eglatoprutug's precise targeting makes it a valuable tool for research focused on c-Kit related pathways and diseases.
Synonyms: ORY012
The Anti-AXL / UFO (ORY012) is a polyclonal antibody specifically designed to target the receptor tyrosine kinase AXL, also known as UFO. This antibody is highly relevant for studies focusing on the pathophysiology and therapeutic targeting of cancers such as glioblastoma multiforme (GBM) and pancreatic cancer. Its specificity for the AXL/UFO receptor makes it an invaluable tool for researchers investigating the role of this kinase in cancer progression and response to therapies.
Synonyms: IBI-315; BH2950
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody engineered to concurrently target and inhibit the human epidermal growth factor receptor 2 (HER2) and the programmed death receptor-1 (PD-1). By binding to these receptors, Fidasimtamab disrupts downstream signaling pathways, thereby exerting potential immunosuppressive and antitumor effects. This antibody facilitates the linkage of PD-1 expressing T cells to HER2 expressing tumor cells, enhancing immune-mediated tumor cell killing. Fidasimtamab is under investigation for its therapeutic efficacy in various oncological applications.
The Anti-FGFR1/CD331 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting FGFR1/CD331. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is crucial for research focusing on the role of FGFR1/CD331 in cellular processes and disease mechanisms, making it an essential tool for both basic research and therapeutic development.
Inetetamab is a monoclonal antibody that specifically targets domain IV of the HER2 receptor. This antibody exhibits antitumor activities either as a standalone treatment or in combination with tyrosine kinase inhibitors. Inetetamab's mode of action and its specificity for the HER2 receptor make it a valuable tool in cancer research, particularly in studies focused on HER2-positive tumors.
Necitumumab is a recombinant human IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR). This antibody is utilized extensively in the study of non-small cell lung cancer (NSCLC), colorectal cancer, and other malignancies characterized by EGFR expression. Its high specificity and affinity for EGFR make it a valuable tool in oncological research, particularly in investigations aimed at elucidating the role of EGFR in tumor pathogenesis and in the development of therapeutic strategies.
Synonyms: MEHD-7945A; RG 7597
Duligotuzumab, also known as MEHD-7945A and RG 7597, is a humanized IgG-κ monoclonal antibody designed for high specificity towards Her3 (ErbB3). This antibody has been engineered for research applications focusing on the ErbB3 signaling pathways, which are critical in the study of cellular growth, differentiation, and survival mechanisms. Duligotuzumab is utilized primarily in cancer research, where ErbB3 plays a significant role in tumor growth and progression.
AFM24 is a bispecific TandAb antibody, produced in Chinese Hamster Ovary (CHO) cells, designed to target both EGFR and Fc-gamma-RIIIA. This antibody comprises a human IgG1-SCFV heavy chain paired with a λ light chain, and has a predicted molecular weight of 74.5 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. AFM24 is applicable in research focusing on the modulation of immune responses and the investigation of EGFR-related signaling pathways in oncology.
Synonyms: SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody designed to specifically target HER3. This antibody effectively inhibits the activation of members of the epidermal growth factor receptor (ErbB) family and their downstream signaling pathways. Seribantumab has demonstrated the ability to suppress neuregulin 1 (NRG1) fusion-dependent tumorigenesis both in vitro and in vivo, showing efficacy in patient-derived models of breast, lung, and ovarian cancers. This makes it a valuable tool for research in cancer biology, particularly in studies focusing on the molecular mechanisms of tumorigenesis and therapeutic antibody development.
The Anti-MSPR/RON/CD136 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the MSPR/RON/CD136 receptor. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 145.74 kDa. For isotype control, researchers should use the Human IgG1 kappa Isotype Control. This antibody is essential for studies focusing on the biological functions and therapeutic targeting of the MSPR/RON/CD136 receptor in various cellular processes and disease states.
Synonyms: RC48-0
Disitamab (RC48-0) is a humanized monoclonal antibody specifically targeting the human epidermal growth factor receptor 2 (HER2). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), including Disitamab vedotin. Disitamab exhibits high specificity and affinity for HER2, making it a valuable tool in targeted cancer therapy research, particularly for the treatment of HER2-positive tumors.
